Comparative Pharmacology
Head-to-head clinical analysis: TOPOTECAN versus TOPOTECAN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TOPOTECAN versus TOPOTECAN HYDROCHLORIDE.
TOPOTECAN vs TOPOTECAN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topotecan is a topoisomerase I inhibitor that binds to the topoisomerase I-DNA complex and prevents religation of single-strand breaks, leading to DNA damage and apoptosis.
Topoisomerase I inhibitor; binds to topoisomerase I-DNA complex, prevents religation of single-strand breaks, leading to DNA damage and apoptosis.
1.5 mg/m² intravenously over 30 minutes daily for 5 consecutive days, repeated every 21 days.
1.5 mg/m² intravenously over 30 minutes daily for 5 consecutive days, repeated every 21 days.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours in patients with normal renal function. In patients with creatinine clearance <20 mL/min, half-life may extend to 4-5 hours.
Clinical Note
moderateTopotecan + Digoxin
"The serum concentration of Digoxin can be increased when it is combined with Topotecan."
Clinical Note
moderateTopotecan + Digitoxin
"Topotecan may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateTopotecan + Deslanoside
"Topotecan may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateTopotecan + Acetyldigitoxin
"Topotecan may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 2-3 hours in patients with normal renal function. In patients with moderate renal impairment (creatinine clearance 20-39 mL/min), half-life is prolonged to about 5 hours, requiring dose adjustment.
Renal excretion accounts for approximately 50-60% of total clearance as unchanged drug. Biliary/fecal elimination is minor, around 20-30% as metabolites. The lactone form is predominantly excreted renally.
Renal excretion accounts for approximately 30% of total clearance as unchanged drug. Biliary/fecal excretion is minor, with less than 2% recovered in feces. The remainder is metabolized primarily via lactone ring hydrolysis to a less active hydroxy acid form, which is also renally eliminated.
Category C
Category C
Antineoplastic (Topoisomerase Inhibitor)
Antineoplastic (Topoisomerase Inhibitor)